877132-72-4Relevant academic research and scientific papers
Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5, 7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5, 6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor
Li, Hui,Tatlock, John,Linton, Angelica,Gonzalez, Javier,Jewell, Tanya,Patel, Leena,Ludlum, Sarah,Drowns, Matthew,Rahavendran, Sadayappan V.,Skor, Heather,Hunter, Robert,Shi, Stephanie T.,Herlihy, Koleen J.,Parge, Hans,Hickey, Michael,Yu, Xiu,Chau, Fannie,Nonomiya, Jim,Lewis, Cristina
supporting information; experimental part, p. 1255 - 1258 (2009/12/26)
The HCV RNA-dependent RNA polymerase has emerged as one of the key targets for novel anti-HCV therapy development. Herein, we report the optimization of the dihydropyrone series inhibitors to improve compound aqueous solubility and reduce CYP2D6 inhibitio
INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
-
Page/Page column 248, (2008/06/13)
The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).
